Advanced Filters
noise

Neoplasms Clinical Trials

A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 14,299 clinical trials
F Francisco Garcia Torres, PhD

Unified Barlow Protocol (UP) in Cancer Survivors for Cognitive Impairments

Background: Cognitive impairment appears frequently in cancer survivors, negatively affecting the quality of life and emotional well-being of patients. This study compares the effectiveness of a well-established treatment (cognitive rehabilitation) with the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) to alleviate these cognitive deficits and evaluate its effect …

18 - 70 years of age All Phase N/A
J Jose Carlos Garrido, PhD

Omega-3 Fatty Acids and Nutritional Support in Gastrointestinal Cancer

Sarcopenia is a frequent complication in patients with cancer and chronic diseases, it is characterized by decreased muscle strength and fatigue due to reduced skeletal muscle mass, which is accompanied by atrophy and decreased quality of muscle tissue. In all cases, it negatively impacts treatment tolerance, clinical outcomes and survival, …

18 years of age All Phase N/A
J Jinsong Lu, MD

Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer

This is a prospective, randomised, multicenter, no placebo-controlled, open label study for evaluating the efficacy and safety of pyrotinib in women with residual invasive HER2-positive breast cancer after neoadjuvant chemotherapy plus anti-HER2 target therapy. The main purpose is to investigate whether pyrotinib can further reduce the risk of recurrence from …

18 - 70 years of age Female Phase 3
J JianZhong Shou, MD

OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer

This phase Ⅰb/Ⅱ study evaluates the safety and efficacy of OH2 for adjuvant therapy in non-muscle-invasive bladder cancer after first-line prophylactic intravesical instillation therapy. OH2 is an oncolytic virus developed upon genetic modifications of the herpes simplex virus type 2 strain HG52, allowing the virus to selectively replicate in tumors. …

18 - 80 years of age All Phase 1/2
L Louis DOUBLET, MD

Anxiolytic Effects of Socio-aesthetics in Cancer Patients Undergoing Chemotherapy

The purpose of the study is to assess the average of the "State Anxiety" score of the State Trait Inventory Anxiety at the end of the third cycle of chemotherapy compared to the pre-treatment score (inclusion)

18 years of age All Phase N/A
S Samah Essam Saber Mahran

The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer

The goal of this clinical trial is to evaluate the protective effect of metformin on nephrotoxicity of cisplatin in patients with bladder cancer. The main questions it aims to answer are: To determine protective effect of metformin on structural and functional kidney injury caused by cisplatin in patients with bladder …

18 - 65 years of age All Phase 4

A Study of Tooth Erosion in People With Esophagogastric Cancer

The researchers are doing this study to find out more about what may lead to the loss of tooth enamel (the thin outer covering of the tooth) and how often it happens in people with esophagogastric cancer, colorectal cancer, pancreatic cancer, breast cancer, head and neck cancer, or non-small cell …

18 years of age All Phase N/A
K Kelly Stratton, MD

Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer

Proposed immunotherapy with an extended course of Sipuleucel-T treatment may induce a more robust immune response and improve the anti-cancer efficacy of Sipuleucel-T in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC).

18 years of age Male Phase 1
T Takehiro Okabayashi

Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP

The effect of neoadjuvant chemotherapy for pancreatic cancer was gradually established. However it has been not clarified which regimen of neoadjuvant treatment for pancreatic cancer is the best.

18 - 85 years of age All Phase 2/3
S Seock-Ah Im

Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

Talazoparib has shown clinical efficacy in breast cancer patients with germline BRCA1 or BRCA2 mutations. Beyond BRCA1 and BRCA2 mutations, it is plausible that talazoparib may have activity in patients with homologous recombination defects (HRD).

19 years of age Female Phase 2

Simplify language using AI